

COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials.

Title: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials.

Publication year: 2021

Journal: Nature reviews. Clinical oncology

Authors: Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, MN, USA.

Society: American College of Cardiology

Origin country: United States

Target countries: United States

DOI: 10.1038/s41571-021-00487-z

PMID: 33723371

Source: <https://pubmed.ncbi.nlm.nih.gov/33723371/>

pmc Nat Rev Clin Oncol Nat Rev Clin Oncol 3814 phenaturepg 101500077 Nature Reviews. Clinical Oncology 1759-4774 1759-4782 pmc-is-collection-domain yes pmc-collection-title Springer Nature - PMC COVID-19 Collection PMC7957448 PMC7957448.1 7957448 7957448 33723371 10.1038/s41571-021-00487-z 487 1 Perspective COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials Desai Aakash 1 Gainor Justin F. 2 Hegde Aparna 3 Schram Alison M. 4 <http://orcid.org/0000-0003-1781-2518> Curigliano Giuseppe 5 Pal Sumanta 6 Liu Stephen V. 7 Halmos Balazs 8 <http://orcid.org/0000-0001-8970-7675> Groisberg Roman 9 Grande Enrique 10 Dragovich Tomislav 11 Matrana Marc 12 Agarwal Neeraj 13 Chawla Sant 14 Kato Shumei 15 Morgan Gilberto 16 <http://orcid.org/0000-0002-5169-7085> Kasi Pashtoon M. 17 Solomon Benjamin 18 Loong Herbert H. 19 Park Haeseong 20 <http://orcid.org/0000-0002-9201-3217> Choueiri Toni K. 21 <http://orcid.org/0000-0002-0758-7911> Subbiah Ishwaria M. 22 Pemmaraju Naveen 23 <http://orcid.org/0000-0002-6064-6837> Subbiah Vivek vsubbiah@mdanderson.org 24 25 26 the COVID19 and Cancer Clinical Trials Working Group 1 grid.66875.3a 0000 0004 0459 167X Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, MN USA 2 grid.32224.35 0000 0004 0386 9924 Department of Medicine, Massachusetts General Hospital, Boston, MA USA 3 grid.265892.2 0000000106344187 Department of Hematology and Oncology, O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL USA 4 grid.51462.34 0000 0001 2171 9952 Memorial Sloan Kettering Cancer Center, New York, NY USA 5 grid.414603.4 Department of Oncology and Hemato-Oncology, University of Milan and European Institute of Oncology, IRCCS, Milan, Italy 6 grid.410425.6 0000 0004 0421 8357 Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA USA 7 grid.213910.8 0000 0001 1955 1644 Department of Developmental Therapeutics, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC USA 8 grid.251993.5 0000000121791997 Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, The Bronx, NY USA 9 grid.430387.b 0000 0004 1936 8796 Department of Melanoma/Sarcoma Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ USA 10 grid.428844.6 Department of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain 11 Department of Hematology/Oncology, MD Anderson Banner Cancer Center, Gilbert, AZ USA 12 Precision Cancer Therapies (Phase I) Research Program, Experimental Therapeutics, Ochsner, New Orleans, LA USA 13 grid.223827.e 0000 0001 2193 0096 Division of Oncology, Department of Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT USA 14 grid.477838.7 Sarcoma Oncology Center, Santa Monica, CA USA 15 grid.266100.3 0000 0001 2107 4242 Center for Personalized Cancer Therapy, Moores Cancer Center, University of California San Diego, La Jolla, CA USA 16 grid.411843.b 0000 0004 0623 9987 Department of Oncology, Skåne University Hospital, Lund, Sweden 17 grid.214572.7 0000 0004 1936 8294 Division of Hematology, Oncology and Blood and Marrow Transplantation, Department of Medicine, University of Iowa, Iowa City, IA USA 18 grid.1055.1 0000000403978434 Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria Australia 19 grid.10784.3a 0000 0004 1937 0482 Department of Clinical Oncology, State Key Laboratory of Translational Oncology, The Chinese University of

Hong Kong, Hong Kong SAR, China 20 grid.4367.6 0000 0001 2355 7002 Division of Oncology, Department of Medicine, Washington University in St. Louis, St Louis, MO USA 21 grid.65499.37 0000 0001 2106 9910 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA USA 22 grid.240145.6 0000 0001 2291 4776 Department of Palliative, Rehabilitation & Integrative Medicine, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX USA 23 grid.240145.6 0000 0001 2291 4776 Department of Leukemia, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX USA 24 grid.240145.6 0000 0001 2291 4776 Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX USA 25 grid.240145.6 0000 0001 2291 4776 Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX USA 26 grid.240145.6 0000 0001 2291 4776 MD Anderson Cancer Network, The University of Texas MD Anderson Cancer Center, Houston, TX USA 15 3 2021 2021 18 5 377516 313 319 16 2 2021 15 03 2021 15 03 2021 12 11 2024 © Springer Nature Limited 2021, corrected publication 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. Author Correction: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials 18 5 23 3 2021 320 320 Nature Reviews. Clinical Oncology 10.1038/s41571-021-00503-2 PMC7985918 33758378 Emerging efficacy data have led to the emergency use authorization or approval of COVID-19 vaccines in several countries worldwide. Most trials of COVID-19 vaccines excluded patients with active malignancies, and thus data on the safety, tolerability and efficacy of the vaccines in patients with cancer are currently limited. Given the risk posed by the COVID-19 pandemic, decisions regarding the use of vaccines against COVID-19 in patients participating in trials of investigational anticancer therapies need to be addressed promptly. Patients should not have to choose between enrolling on oncology clinical trials and receiving a COVID-19 vaccine. Clinical trial sponsors, investigators and treating physicians need operational guidance on COVID-19 vaccination for patients with cancer who are currently enrolled or might seek to enrol in clinical trials. Considering the high morbidity and mortality from COVID-19 in patients with cancer, the benefits of vaccination are likely to far outweigh the risks of vaccine-related adverse events. Herein, we provide operational COVID-19 vaccine guidance for patients participating in oncology clinical trials. In our perspective, continued quality oncological care requires that patients with cancer, including those involved in trials, be prioritized for COVID-19 vaccination, which should not affect trial eligibility.

Patients with cancer have a high risk of morbidity and mortality from COVID-19. The rapid development of COVID-19 vaccines has provided new hope of mitigating the disease. Herein, the COVID19 and Cancer Clinical Trials Working Group calls for prioritization of patients with cancer, importantly including those participating in oncology clinical trials, for COVID-19 vaccination. The authors also provide operational COVID-19 vaccine guidance for patients participating in oncology clinical trials.

As 2020 ended, we saw a glimmer of hope against the coronavirus disease 2019 (COVID-19) pandemic, with promising safety and efficacy data emerging from clinical trials of several vaccines targeting the COVID-19 causative virus, SARS-CoV-2 (refs 1 – 5). As a result, the FDA has granted emergency use authorization (EUA) to BNT162b2 and to mRNA-1273, two lipid nanoparticle-formulated, nucleoside-modified mRNA-based vaccines encoding the prefusion spike glycoprotein of SARS-CoV-2, and to Ad26.COV2.S, a replication-incompetent adenovirus type 26 (Ad26) vector vaccine encoding a stabilized variant of the SARS-CoV-2 spike protein 1 , 2 . In addition, the UK Medicines and Healthcare products Regulatory Agency has approved the ChAdOx1 nCoV-19 vaccine, comprising a recombinant, replication-deficient chimpanzee adenovirus vector also encoding the SARS-CoV-2 spike glycoprotein 5 . Encouraging preliminary safety and efficacy results have also been reported with the rAd26 and rAd5 heterologous prime–boost recombinant adenovirus vector COVID-19 vaccine developed in Russia and with the CoronaVac inactivated SARS-CoV-2 vaccine developed in China 3 , 4 , both of which have been authorized for use in their country of origin. Currently, more than 60 different COVID-19 vaccines

are at different stages of clinical development. Limited data are available, however, on the safety, tolerability and efficacy of COVID-19 vaccines in patients with cancer, owing to the exclusion of patients with active malignancies from most of the vaccination trials⁶. For example, among the 43,540 participants enrolled in the trial of BNT162b2, only 3.7% were reported to have cancer. Overall, only ten patients had developed severe COVID-19 at the time of reporting of initial results from this trial, one in the vaccine arm and nine in the placebo arm (whether any of these patients had cancer was not reported)². Thus, generating more data on the efficacy of COVID-19 vaccines in patients with cancer, especially in the setting of active cancer therapy, is a priority.

Multiple studies have revealed that patients with cancer have an increased risk of complications and mortality from COVID-19, including 30-day mortality of 30% in hospitalized patients with COVID-19 and cancer compared with 21% in those without cancer^{7–14}. Given the greater severity of the disease and higher risk of death, patients with cancer are considered a high-priority subgroup for COVID-19 vaccination. In the USA, multiple organizations, including the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO) and the Association of American Cancer Institutes (AACI), have urged the Centres for Disease Control and Prevention (CDC) to prioritize patients with cancer for COVID-19 vaccination^{15, 16}. The European Society for Medical Oncology (ESMO), the Society for Immunotherapy of Cancer (SITC), the Spanish Medical Oncology Society (SEOM) and the National Comprehensive Cancer Network (NCCN) COVID-19 Vaccination Advisory Committee have released their preliminary recommendations supporting vaccination in all patients with cancer, including those receiving active therapy^{17–20}. Exception from vaccination would apply to patients undergoing transplantation or adoptive cell therapy, for whom immunization should be delayed for at least 3 months to maximize vaccine efficacy, in line with the general recommendations of delaying vaccinations following such highly immunosuppressive therapies¹⁸. The NCCN committee also called for the inclusion of patients with cancer in the CDC priority group for phase Ib/Ic of COVID-19 vaccine distribution¹⁸, which includes essential workers (such as those involved in law enforcement, teachers and firefighters), adults ≥ 65 years of age and individuals 16–64 years of age with high-risk medical conditions²¹. However, the NCCN guidelines encourage discussions between clinical trial leads and patients enrolled on their trials to prevent protocol violations or exclusions¹⁸, and most of the other guidelines are silent on the language regarding patients enrolled in cancer clinical trials.

Given that the current vaccines are 'authorized' and not 'approved' in many countries, a question remains as to whether they are considered investigational. Recognition of this issue is important because the protocols of many trials include criteria prohibiting the concomitant use of other investigational agents, although usually such criteria are meant to apply to other anticancer therapies, specifically. In January 2021, the FDA provided clarification that receipt of a COVID-19 vaccine under an EUA is not considered to constitute treatment with an investigational product²². Similarly, other regulatory authorities should consider providing such clarification and guidance. Furthermore, no data are available on the safety or efficacy of COVID-19 vaccines in patients enrolled on oncology clinical trials, especially of novel investigational agents; therefore, rapidly generating data in this subset of patients is crucial. Indeed, several questions remain unanswered, including the time needed for immunity to develop, the duration of immunity, the effects of different systemic treatments on immunity and the optimal time points and posology of vaccine administration in patients with cancer. Given the experience with prior vaccines, such as those against influenza²³, no serious safety concerns are expected in patients with cancer. Moreover, the currently available vaccines do not contain functional coronavirus and are, therefore, hypothesized to have no possibility of causing an active infection, even in immunosuppressed patients.

Given the risk posed by the COVID-19 pandemic, prompt decisions need to be made regarding the use of any vaccine, including those approved and/or authorized for use against SARS-CoV-2, in patients treated with investigational agents on clinical trials. Patients with cancer should not have to choose between enrolling on an oncology clinical trial and receiving a COVID-19 vaccine. On this background, clinical trial sponsors, investigators and treating physicians need operational guidance on COVID-19 vaccination for patients with cancer who are currently participating in oncology clinical

trials or might be considering or seeking trial enrolment.

Clinical trials are integral to high-quality oncological care and are crucial for improvements in the management of cancer. During the COVID-19 pandemic, patient enrolment has decreased across oncology trials of all phases (from trials of screening and/or prevention strategies to phase I, II and III trials) 24 , 25 , which will likely hinder scientific and medical progress. For many patients with rare diseases or specific biomarker-driven cancers, trials testing novel investigational treatments might be the best therapeutic option — or sometimes the only option — following receipt of standard-of-care therapies. Although oncology trials are often complex, with mandated protocol schedules (including laboratory tests, scans, biopsies and clinical visits) at specific time points, both the FDA and the EMA have recognized that protocol deviations might be unavoidable and protocol modifications might also be required to maximize patient safety during the COVID-19 pandemic 26 , 27 . This timely regulatory guidance has facilitated investigators, industry partners and academic centres in working with their institutional review boards to navigate the pandemic and has made the clinical trials more patient-centric 28 . We believe that COVID-19 vaccination provides another such opportunity to focus on ‘patient safety first and then protocols later’ in the context of clinical trials. Depriving eligible and vulnerable patients with cancer of COVID-19 vaccination would fall below the standard of care; therefore, recruiting any patient with cancer to any trial that prevented or discouraged them from receiving a vaccine with at least EUA would be unethical. Herein, we outline COVID-19 vaccine guidance for patients participating in oncology clinical trials.

A COVID-19 vaccine that has been authorized by the appropriate regulatory authorities in the respective countries should not be considered as an investigational agent for the purposes of oncology clinical trials. An approved and/or authorized vaccine should be considered as a concomitant medication and entered as such in the electronic record. The dates of first and second vaccinations, the doses used and any adverse effects should also be recorded. This information might be helpful in the future to evaluate the effects of COVID-19 vaccination on the safety and efficacy of anticancer therapies, in particular, immunotherapies.

COVID-19 vaccines should be offered to all patients with cancer, including those participating in clinical studies. Indeed, we recommend that immunization against COVID-19 be the norm, not an exception, for patients participating in trials of cancer treatments. Moreover, eligible patients who have received COVID-19 vaccines should be accepted on all phases of clinical trials.

We further recommend that patients with cancer in general, including those enrolled on clinical trials, should be prioritized for COVID-19 vaccination. Patients participating in clinical trials often have progressive advanced-stage cancer, are undergoing active treatment and usually make several visits to clinics and hospitals for study-related procedures, which potentially increases their exposure to SARS-CoV-2 infection at multiple points. Thus, prioritization for vaccination is imperative, particularly considering that patients with cancer also seem to have an increased risk of severe COVID-19 and complications and mortality from the disease 7 – 14 . Due consideration should also be given to other well-recognized risk factors for severe COVID-19, such as advanced age (≥ 65 years), comorbidities (for example, chronic pulmonary, cardiovascular or renal disease) and other sociodemographic factors (such as overcrowded housing, single-parent households and ethnicity) 29 , when prioritizing patients with cancer for vaccination, with priority given to those at most risk.

In addition to patients with cancer, we also suggest that caregivers, household members and/or close contacts of these patients (adults regardless of age) should be vaccinated as early as possible based on the local guidelines for public vaccinations. This strategy will enable further reductions in risk of SARS-CoV-2 transmission from close contacts for high-risk patients with cancer.

Preference should be given to approved and/or authorized vaccines for use in patients enrolled on oncology clinical trials. In situations in which an authorized vaccine is unavailable, if a specific trial of a COVID-19 vaccine is available to patients with cancer (for example, the vaccination against

COVID in cancer (VOICE) study (NCT04715438), a prospective, national, multicentre, longitudinal, multi-cohort study in patients with solid malignancies undergoing active anticancer treatment 30 , or any studies testing booster doses or revaccination schedules in immunocompromised patients that become available in the future) 31 , patients who are participating in an oncology clinical trial should not be excluded from the vaccine trial. Moreover, loosening the eligibility criteria of all trials of COVID-19 vaccines to permit enrolment of patients with cancer, including those receiving investigational therapies, would be prudent.

For patients currently enrolled on phase I trials, the timing of vaccination should be based on the type of anticancer treatment and the stage of the trial (dose escalation versus dose expansion) (Table 1). Due consideration should be given to any confounding variables relating to the expected adverse effects of the investigational drugs and vaccines, especially during the dose-limiting toxicity (DLT) window 32 , to avoid overlapping toxicities that might compromise the safety and tolerability of either treatment. Patients entering clinical trials, especially phase I trials, could receive the first dose of a COVID-19 vaccine while undergoing screening procedures for trial eligibility. If clinical trial sponsors have specific, mechanism-based concerns regarding the timing of vaccination relative to the investigational agents (for example, agents with cytokine-release syndrome potential or anti-CD20 antibodies), they should issue immediate guidance on vaccination of patients who enrol on the trial. Table 1 COVID-19 vaccine guidance for patients participating in oncology clinical trials

Dose-escalation phase: with most anticancer agents, including TKIs, avoid vaccination on cycle 1 day 1. In general, defer initiation of the first cycle of investigational therapy until after all vaccine adverse effects have improved to grade ≤ 1 and for at least until 72 h after vaccination

For immunotherapy agents with no known potential for cytokine-release syndrome, avoid vaccination on the day of infusions of intravenous immunotherapy, at least in the DLT period

For immunotherapy agents associated with a potential risk of cytokine-release syndrome, defer vaccination until after the DLT window or delay administration of the investigational agent for 2 weeks after vaccine administration

For first-in-human agents with an unknown adverse effect profile, delay administration until all adverse effects of the vaccine should have resolved to grade ≤ 1

Recommendations on primary vaccination and schedules, and guidance on revaccination or additional doses of mRNA-based COVID-19 vaccines and other COVID-19 vaccines should be viewed as preliminary in patients with cancer, including those participating in clinical trials, and might be updated as additional information becomes available 35 . It should be noted that some of these recommendations are based on those made for patients with cancer in general by other organizations, such as the NCCN, ASCO, ESMO or SITC 17 – 20 , 41 . This table provides operational guidance and is a panel summary. This guidance is for informational use only in the rapidly evolving COVID-19 pandemic. This information does not constitute medical or legal or regulatory advice, does not endorse any specific products or therapies, does not recommend or mandate any particular course of medical care, and is not a statement of the standard of care. CAR, chimeric antigen receptor; COVID-19, coronavirus disease 2019; DLT, dose-limiting toxicity; TKI, tyrosine kinase inhibitor.

Some adverse events seen with COVID-19 vaccines might manifest similarly to those of novel anticancer agents in early phase trials, especially hypersensitivity reactions. To minimize the need to determine whether a patient is experiencing hypersensitivity to an investigational product or an adverse event related to vaccine administration, consideration should be given to the timing of vaccination based on the mechanism of action of the anticancer agents. Most hypersensitivity reactions to novel agents are observed within the first one or two doses of monoclonal antibodies or within the first 1–2 weeks after initiation of therapy with tyrosine kinase inhibitors 33 . This pattern might be helpful when determining whether the causality of an adverse event is related to the study

treatment or the vaccine. If possible, we recommend avoiding administration of an investigational agent within 48–72 h of vaccination to minimize confusion and/or inaccurate attribution of adverse event causation.

The currently available vaccines should not be a contraindication in patients with controlled HIV infection (or other immunocompromised states) and cancer. However, such patients should be counselled regarding the lack of data on the safety and particularly the efficacy of COVID-19 vaccination, especially with novel mRNA-based vaccines, in this setting.

In general, we recommend that patients with solid tumours or haematological malignancies who are receiving cytotoxic therapies, targeted therapies, hormone therapies and/or immunotherapies on a clinical trial should be vaccinated against COVID-19 at the earliest available opportunity. The suggested vaccination schedules for such patients can vary according to the type of trial, disease and cancer treatment (Table 1). The only exception to this rule relates to patients on clinical trials involving transplantation or adoptive cell therapies: vaccine administration might need to be delayed for ≥ 3 months to enable these patients to regain adequate immune function, given that potential graft versus host disease and the immunosuppressive regimens used are expected to blunt immune responses to any vaccine. Other considerations in patients with haematological malignancies include the timing of vaccine administration around infusions required for various chemotherapy regimens and decreased blood counts, particularly neutropenia, lymphopenia and thrombocytopenia, according to local practices at each hospital and the treating physician's judgement in the patient's best interest.

For patients receiving cytotoxic chemotherapy, given the lack of data on the optimal timing of vaccination, we recommend COVID-19 vaccination whenever a vaccine is available (Table 1). Data from a study on the optimal timing of influenza vaccination during 3-week chemotherapy cycles indicate that antibody responses to the vaccine are similar in patients inoculated concurrently with chemotherapy administration and in those inoculated during the cytopenic period of the chemotherapy cycle ³⁴. Extrapolating from the findings of this study, we recommend that COVID-19 vaccines should be administered whenever available, until more data on optimal timing become available. This recommendation might be updated when further data on COVID-19 vaccination emerge.

According to the CDC ³⁵, at this time, revaccination is not recommended after immune competence is regained in persons who received one of the authorized mRNA-based COVID-19 vaccines during chemotherapy or treatment with other immunosuppressive drugs. However, recommendations on revaccination or additional doses of COVID-19 vaccines might be updated as additional information becomes available.

For patients undergoing elective surgery, the work-up time should enable COVID-19 vaccination before surgery. In the case of urgent or emergent surgery, patients can be vaccinated postoperatively, after patient recovery.

For participants in breast cancer screening trials, consideration should be given to the fact that COVID-19 vaccination can cause transient lymphadenopathy ^{36, 37}. Therefore, if possible and if patient management will not be unjustifiably interrupted, screening examinations should be conducted either before the first dose of a COVID-19 vaccine or 4–6 weeks after the second dose, as recommended previously by other groups ^{36, 37}.

Importantly, long-term pharmacovigilance is required for all patients who receive any COVID-19 vaccine. Any emerging concerns regarding the safety or efficacy of COVID-19 vaccines should be recorded appropriately.

We encourage, when possible, the inclusion of the vaccination status of oncology clinical trial participants in the data record. This practice will enable accurate assessment and attribution of

adverse events, which could be sub-stratified for the vaccinated and unvaccinated subgroups, wherever feasible, for further analysis. COVID-19 vaccination details (including vaccine name, batch and manufacturer, dose, date of administration and whether the right or left arm was injected) should be captured as a concomitant medication to enable better assessment of the overall effect of COVID-19 vaccination on oncology trial results.

Other reasons for delaying COVID-19 vaccination of participants in oncology clinical trials, such as recent exposure to COVID-19 or previous allergic or anaphylactic reactions to vaccine components, should be consistent with the general CDC or WHO guidelines 38 , 39 . We hope that additional large-cohort trials and real-world data on COVID-19 vaccines with longer follow-up durations will provide timely information on the effectiveness of the vaccines in patients receiving different cancer treatments; however, the current situation requires swift action to prevent the potential harm of delaying COVID-19 vaccination for this vulnerable subgroup.

To gain a deeper understanding of patients' experiences when receiving treatment on a specific trial, the systematic integration of patient-reported outcomes and other quality-of-life assessments longitudinally throughout the course of therapy is suggested when possible. This awareness of both therapy-related and cancer-related symptom burden over time while patients are on a trial will provide crucial information for the frontline clinical teams as well as patients and their families to guide decision-making and the selection of therapies that are in line with their overall goals and values.

Mobilization efforts from local and state governments and increased flexibility from protocol administrators are required to bring widespread COVID-19 vaccination of patients with cancer to fruition. At the level of investigational centres, ethics committees should be more understanding in cases of protocol deviations, especially if the language in specific protocols is not clear or updated with regard to COVID-19 vaccinations. Allowances for COVID-19 vaccination should ideally be documented in the protocol. Any protocol deviations should be documented, however, considering that such deviations are generally made in the interest of patient safety.

Clinical trial sponsors have begun to roll out guidance on COVID-19 vaccination to investigators, even providing appropriate timing of when study medications should be taken (for example, at least 2 h before or after administration of the vaccine). The sponsors might also request that the electronic data capture systems be updated to reflect this vaccination and to document any associated adverse events. Importantly, major research networks such as the National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP), the Experimental Therapeutics Clinical Trials Network (ETCTN) and the SWOG Cancer Research Network 40 have granted broad permission for, and indeed encouraged, COVID-19 vaccination of participants on their respective trials. Their guidance includes capturing receipt of the vaccine in the medical history, if received before trial enrolment, or as a concomitant medication if administered after enrolment. This kind of clear precedent is welcome and gives individual investigators the freedom to encourage vaccination of their trial patients without trepidation. Furthermore, nationwide coordinated research efforts, such as the NCI Serological Sciences Network for COVID-19 (SeroNet), are studying the immune response to COVID-19, with the aim of combating the pandemic by accelerating the development of treatments and vaccines.

Lastly, advocacy for patients with cancer, including those involved in clinical trials, by their caregivers, physicians and other health-care professionals is imperative to convince stakeholders to consider this group as a high priority. Guidance from the FDA, EMA, NCI and other cancer-focused organizations worldwide might also be needed 41 . Meanwhile, all close contacts of such patients should continue to wear masks, adhere to social distancing guidelines and follow other recommendations, including avoiding unnecessary travel, in order to reduce the risk of SARS-CoV-2 infection and, thus, COVID-19. Given the need to generate data on the immunogenicity of vaccines during systemic cancer therapy, we encourage patient participation in such studies if available locally.

In summary, COVID-19 vaccination, where authorized or approved, should be considered a standard of care for patients with cancer who are currently enrolled on investigational trials. Uncommon exceptions might occur when the principal investigator or treating physician considers use of the vaccine not to be safe or in the patient's best interest. Current knowledge of the safety and efficacy of the authorized COVID-19 vaccines in patients with cancer and particularly those receiving active treatment is limited, although the benefits likely outweigh the risks of vaccine-related adverse effects, considering the high risk of morbidity and mortality from COVID-19 in patients with cancer. Moreover, equitable access to cancer clinical trials and COVID-19 vaccines is imperative. Indeed, continued quality oncological care requires that patients on clinical trials be prioritized for COVID-19 vaccination, which, in and of itself, should not affect clinical trial eligibility.

Nature Reviews Clinical Oncology thanks F. Barlesi, J. Gulley, J. Kimmelman and J. Spicer for their contribution to the peer review of this work.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

FDA and COVID-19 vaccines: <https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines>

NCI Serological Sciences Network for COVID-19 (SeroNet): <https://www.cancer.gov/research/key-initiatives/covid-19/coronavirus-research-initiatives/serological-sciences-network>

A full list of members and affiliations is present at the end of the paper.

A Correction to this paper has been published: 10.1038/s41571-021-00503-2

The work of the authors is supported by National Institutes of Health grant R01CA242845 (to V.S.), The Cancer Prevention and Research Institute of Texas (RP1100584), the Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, 1U01 CA180964, NCATS Grant UL1 TR000371 (Center for Clinical and Translational Sciences), and the MD Anderson Cancer Center Support Grant (P30 CA016672). A.M.S. acknowledges support from Memorial Sloan Kettering Cancer Center P30 CA008748 grant.

A.D., A.H., R.G., E.G., M.M., S.C., G.M., P.M.K., B.S., H.H.L., H.P., N.P. and V.S. researched data for the article. A.D., J.F.G., A.H., A.M.S., G.C., S.P., S.V.L., B.H., T.D., N.A., S.C., S.K., T.K.C., I.M.S., N.P. and V.S. made substantial contributions to discussions of content. A.D., J.F.G., A.M.S., G.C., S.V.L., N.A., I.M.S., N.P. and V.S. wrote the manuscript. A.D., J.F.G., A.H., A.M.S., G.C., S.P., S.V.L., B.H., R.G., E.G., T.D., M.M., N.A., S.C., S.K., G.M., B.S., H.H.L., H.P., T.K.C., I.M.S., N.P. and V.S. reviewed and edited the manuscript before submission.

J.F.G. has served as a compensated consultant or received honoraria from Agios, Amgen, Ariad/Takeda, Array Biopharma, AstraZeneca, Blueprint, Bristol-Myers Squibb (BMS), EMD Serono, Genentech/Roche, Gilead, GlydeBio, Incyte, Loxo Oncology/Lilly, Merck, Mirati, Novartis, Oncorus, Pfizer and Regeneron; has received research support from Ariad/Takeda, Genentech/Roche and Novartis; institutional research support from Adaptimmune, Alexo, Array Biopharma, Blueprint, BMS, Jounce, Merck, Moderna, Novartis and Tesaro; and has an immediate family member who is an employee of Ironwood Pharmaceuticals. G.C. has served on advisory boards for AstraZeneca, Daiichi Sankyo, Ellipsis, Genomic Health, Lilly, Novartis, Roche and Veracyte. S.V.L. has served on advisory boards and/or consulted for Amgen, AstraZeneca, Beigene, Blueprint, BMS, Daiichi Sankyo, G1 Therapeutics, Genentech, Guardant Health, Inivata, Janssen, Jazz, Lilly, Merck, PharmaMar, Pfizer, Regeneron and Takeda; and declares research grants (to his institution) from Alkermes, AstraZeneca, Bayer, Blueprint, BMS, Corvus, Genentech, Lilly, Lycera, Merck, Merus, Pfizer, Rain, RAPT, Spectrum and Turning Point Therapeutics. B.H. reports research funding (to his institution) from AbbVie, Advaxis, Amgen, AstraZeneca, Blueprint,

BMS, Boehringer Ingelheim, Elevation, GlaxoSmithKline, Lilly, Merck, Mirati, Novartis, and Pfizer; and advisory boards consulting roles for Amgen, Apollomics, AstraZeneca, BMS, Boehringer Ingelheim, Guardant Health, Merck, Novartis, Pfizer and TPT. R.G. has received honoraria from Regeneron. E.G. has received honoraria for advisory boards, meetings and/or lectures from Adacap, BMS, Celgene, Eisai, Eusa Pharma, Ipsen, Lexicon, MSD, Novartis, Pfizer, Pierre Fabre, Roche and Sanofi-Genzyme; and unrestricted research grants from AstraZeneca, Ipsen, Lexicon, MTEM/Threshold, Pfizer and Roche. T.D. declares clinical research support/grants (to his institution) from BMS, Lilly, Exelixis, Holystone, Mirati, Novacure, Pharmacyclics and RAPT Pharma. M.M. has been a consultant for AstraZeneca, Dispersol and Strata Oncology; and has received speaker's bureau fee from Astellas, AstraZeneca, BMS, Eisai, Janssen, Merck and Seagen N.A. has served as a consultant to Astellas, AstraZeneca, Aveo, Bayer, BMS, Calithera, Clovis, Eisai, Lilly, EMD Serono, Exelixis, Foundation Medicine, Genentech, Janssen, Merck, MEI Pharma, Nektar, Novartis, Pfizer, Pharmacyclics and Seattle Genetics. S.K. has served as a consultant for Foundation Medicine; has received a speaker's fee from Roche; has served on advisory boards for Pfizer; and has received research funding from ACT Genomics, Konica Minolta, OmniSeq and Sysmex. P.M.K. has served as a consultant and/or advisory board member for Foundation Medicine, Ipsen, Natera, QED and Taiho Oncology; and declares clinical trials involvement and/or funding from AstraZeneca, Boston Scientific and TerSera. H.P. declares research funding/grant support for clinical trials (to her institution) from Ambrx, Amgen, Aprea Therapeutics, Array BioPharma, Bayer, BeiGene, BJ Bioscience, BMS, Daiichi Sankyo, Elicio Therapeutics, Lilly, EMD Serono, Genentech, Gilead Sciences, GlaxoSmithKline, Gossamer Bio, Hoffman-LaRoche, Hutchison MediPharma, ImmuneOncia Therapeutics, Incyte, Jounce, Mabspace Biosciences, MacroGenics, MedImmune, Medivation, Merck, Millennium, Mirati Therapeutics, Novartis Pharmaceuticals, Oncologie, Pfizer, PsiOxus Therapeutics, Puma Biotechnology, Regeneron Pharmaceuticals, Seattle Genetics, Synermore Biologics, Taiho Pharmaceutical, TopAlliance Biosciences, Turning Point Therapeutics, Vedanta Biosciences, Vertex Pharmaceuticals and Xencor. T.K.C. reports institutional and personal research support from Alexion, Analysis Group, AstraZeneca, Bayer, BMS/ER Squibb and Sons, Calithera, Cerulean, Corvus, Eisai, Exelixis, F. Hoffmann-La Roche, Foundation Medicine, Genentech, GlaxoSmithKline, Ipsen, Lilly, Merck, Novartis, Peloton, Pfizer, Prometheus Labs, Roche, Roche Products, Sanofi/Aventis, Takeda and Tracoon; honoraria from Alexion, American Society of Medical Oncology, Analysis Group, AstraZeneca, Bayer, BMS/ER Squibb and Sons, Cerulean, Clinical Care Options, Corvus, Eisai, EMD Serono, Exelixis, F. Hoffmann-La Roche, Foundation Medicine, Genentech, GlaxoSmithKline, Harborside Press, Heron Therapeutics, Ipsen, Kidney Cancer Journal, Lancet Oncology, Lilly Oncology, L-path, Merck, Michael J. Hennessy (MJH) Associates (Healthcare Communications Company with several brands such as OnClive, PeerView and PER), Navinata Healthcare, NCCN, New England Journal of Medicine, Novartis, Peloton, Pfizer, Platform Q, Prometheus Labs, Research to Practice, Roche, Roche Products, Sanofi/Aventis and Up-to-Date; consulting or advisory roles with Alexion, Analysis Group, AstraZeneca, Bayer, BMS/ER Squibb and Sons, Cerulean, Corvus, Eisai, EMD Serono, Exelixis, Foundation Medicine, Genentech, GlaxoSmithKline, Heron Therapeutics, Ipsen, Lilly, Lilly Ventures, Merck, NCCN, Novartis, Peloton, Pfizer, Pionyr, Prometheus Labs, Roche, Sanofi/Aventis, Tempest and Up-to-Date; stock/option ownership in Pionyr and Tempest; present or past leadership roles as Director of GU Oncology Division at the Dana-Farber Cancer Institute (DFCI) and past President of Medical Staff at DFCI, a member of NCCN Kidney panel and the GU Steering Committee, past chairman of the Kidney Cancer Association Medical and Scientific Steering Committee, a member of the KidneyCan Advisory board, Kidney Cancer Research Summit co-chair (2019–present); patents, royalties or other intellectual properties related to biomarkers of immune checkpoint blockers and circulating free methylated DNA; and travel, accommodation, expenses, in relation to consulting, advisory roles or honoraria. N.P. serves on the ASH Communications and ASCO Leukemia advisory panels; has received consultant fees from Blueprint, BMS, ImmunoGen, Pacylex Pharmaceuticals; grants from Affymetrix and the Sagerstrong Foundation; honoraria from AbbVie, Blueprint, Celgene, DAVA Oncology, Incyte, LFB Biotechnologies, MustangBio, Novartis, Roche Diagnostics, Springer Science & Business Media and Stemline Therapeutics; research support from AbbVie, Affymetrix, Celgene, Collectis, Daiichi Sankyo, Novartis, Plexxikon, Samus Therapeutics and Stemline Therapeutics; and travel support from AbbVie, Celgene, DAVA Oncology, MustangBio and Stemline Therapeutics. V.S. declares research funding/grant support

for clinical trials (to his institution) from AbbVie, Agensys, Alfa-Sigma, Altum, Amgen, Bayer, Berghealth, Blueprint, Boston Biomedical, Boston Pharmaceuticals, D3, Dragonfly Therapeutics, Exelixis, Fujifilm, Idera Pharma, Incyte, Inhibrx, Loxo oncology, MedImmune, Multivir, NCCN, Novartis, Pharmamar, Pfizer, Takeda and Turning Point Therapeutics; has received travel funding from ASCO, ESMO, Helsinn, Incyte, Novartis and Pharmamar; and has served on advisory boards for AstraZeneca/MedImmune, Helsinn, Incyte, Loxo Oncology/Lilly, Novartis, QED Pharma, R-Pharma US and Signant Health. The other authors declare no competing interests.